Human Papillomavirus Vaccines: Successes and Future Challenges

dc.contributor.authorPerez, Samara
dc.contributor.authorZimet, Gregory D.
dc.contributor.authorTatar, Ovidiu
dc.contributor.authorStupiansky, Nathan W.
dc.contributor.authorFisher, William A.
dc.contributor.authorRosberger, Zeev
dc.contributor.departmentPediatrics, School of Medicineen_US
dc.date.accessioned2019-04-25T18:33:39Z
dc.date.available2019-04-25T18:33:39Z
dc.date.issued2018-09
dc.description.abstractOver a decade has passed since the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received unequivocal backing from the scientific and medical communities, yet continue to be debated in the media and within the general public. The current review is an updated examination that the authors made five years ago on some of the key sociocultural and behavioral issues associated with HPV vaccine uptake and acceptability, given the changing HPV vaccine policies and beliefs worldwide. We explore current worldwide HPV vaccination rates, outline HPV vaccine policies, and revisit critical issues associated with HPV vaccine uptake including: risk compensation, perceptions of vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP) recommendation and communication. While public scrutiny of the vaccine has not subsided, empirical evidence supporting its safety and efficacy beyond preventing cervical cancer has amassed. There are conclusive findings showing no link that vaccinated individuals engage in riskier sexual behaviors as a result of being immunized (risk compensation) both at the individual and at the policy level. Finally, HCP recommendation continues to be a central factor in HPV vaccine uptake. Studies have illuminated how HCP practices and communication enhance uptake and alleviate misperceptions about HPV vaccination. Strategies such as bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase rates. The successes of HPV vaccination outweigh the controversy, but as the incidence of HPV-related cancers rises, it is imperative that future research on HPV vaccine acceptability continues to identify effective and targeted strategies to inform HPV vaccination programs and improve HPV coverage rates worldwide.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationPerez, S., Zimet, G. D., Tatar, O., Stupiansky, N. W., Fisher, W. A., & Rosberger, Z. (2018). Human Papillomavirus Vaccines: Successes and Future Challenges. Drugs, 78(14), 1385–1396. https://doi.org/10.1007/s40265-018-0975-6en_US
dc.identifier.urihttps://hdl.handle.net/1805/18953
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s40265-018-0975-6en_US
dc.relation.journalDrugsen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectHPV vaccineen_US
dc.subjectuptake ratesen_US
dc.subjectmisconceptionsen_US
dc.titleHuman Papillomavirus Vaccines: Successes and Future Challengesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Perez_2018_human.pdf
Size:
796.82 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: